Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026)
Pharvaris' (PHVS) quarterly Cash from Investing Activities came in at -$60992.3 in Q1 2026, up 63.99% YoY from -$37193.7 in Q1 2025, and down 3306.82% on a QoQ basis from -$1790.3 in Q4 2025.
Analysis
Pharvaris (PHVS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Cash from Investing Activities data on file, last reported at -$60992.3 in Q1 2026.
- Quarterly Cash from Investing Activities rose 63.99% year-over-year to -$60992.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65829.1 (up 90.87% YoY) and the FY2025 annual result came in at -$185988.4, up 68.06% from the prior year.
- Cash from Investing Activities fell to -$60992.3 in Q1 2026, from -$1790.3 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $58.9 billion in Q3 2023 to a low of -$58.9 billion in Q2 2023.
- A 5-year average of -$1.1 million and a median of -$30535.2 in 2023 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 114742419.94% in 2023, down 236328759.87% in 2023.
- Tracing PHVS's Cash from Investing Activities over 5 years: stood at -$24117.6 in 2022, then declined by 26.61% to -$30535.2 in 2023, then sank by 463.14% to -$171955.2 in 2024, then soared by 98.96% to -$1790.3 in 2025, then tumbled by 3306.82% to -$60992.3 in 2026.
- The last three Cash from Investing Activities figures came in at -$60992.3 (Q1 2026), -$1790.3 (Q4 2025), and -$21877.7 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Pharvaris | 2.10 Bn | 1.73 Bn | 85,072.10 | -31,275.67 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31,275.67 |
| Mar 31, 2026 | -60,992.34 |
| Dec 31, 2025 | -1,790.30 |
| Sep 30, 2025 | -21,877.70 |
| Jun 30, 2025 | 18,831.28 |
| Mar 31, 2025 | -169,356.55 |
| Dec 31, 2024 | -171,955.17 |
| Sep 30, 2024 | 77.80 Bn |
| Jun 30, 2024 | -76.29 Bn |
| Mar 31, 2024 | -33,360.00 |
| Dec 31, 2023 | -30,535.17 |
| Sep 30, 2023 | 58.91 Bn |
| Jun 30, 2023 | -58.93 Bn |
| Mar 31, 2023 | -20,434.28 |
| Dec 31, 2022 | -24,117.63 |
| Sep 30, 2022 | 50.15 Bn |
| Jun 30, 2022 | -53.07 Bn |
| Mar 31, 2022 | -29,598.29 |
| Dec 31, 2021 | -78,405.48 |
| Sep 30, 2021 | -32,949.29 |